Dova, Salix partner to promote Doptelet for patients with liver disease

Dova Pharmaceuticals and Salix Pharmaceuticals entered into an exclusive agreement to promote Doptelet, according to a press release.

Doptolet (avatrombopag, Dova) is a recently FDA-approved treatment for thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.

“Salix considers liver disease a strategic therapeutic area of focus,” Mark McKenna, president of Salix Pharmaceuticals, said in the release. “Adding Doptelet to our portfolio will enable our sales force to promote yet another innovative product that addresses a true unmet need in the marketplace.”

As part of the co-promotion arrangement, Salix intends to deploy approximately 100 sales specialists to promote Doptotelet to gastroenterology professionals in mid-October. Dova will also continue its commercial efforts in targeting hepatologists and interventional radiologists.

“We are delighted to be working with Salix, a company considered by many to have the preeminent gastroenterology sales force in the United States,” Alex C. Sapir, president and of Dova Pharmaceuticals, said in the release. “Given Salix’s presence and strong reputation within large gastroenterology group practices coupled with the early interest we are seeing among the gastroenterology community, we are excited to see the impact this partnership will bring to Doptelet and to patients.”

Reference: www.dova.com; www.salix.com